Fake COVID-19 news makes you want to treat yourself on the cheap

fake news
Credit: CC0 Public Domain

People exposed to fake news during the already uncertain COVID-19 era are simultaneously compelled to treat themselves and to try to save money, according to new research from CU Boulder and the University of New Hampshire.

The findings are published in an upcoming edition of the Journal of the Association for Consumer Research.

Participants exposed to fake news said they felt more uncertainty about their lives. The researchers found this effect was compounded by the pandemic. It even occurred when researchers reminded participants that fake news exists.

The researchers then asked participants a series of questions about making hypothetical choices between premium or cost-effective food and grocery products.

“The finding that surprised us is that this uncertainty can cause people to feel a joint desire to save their money for a murky future and also to spend a little bit to make themselves feel better about

Read More

‘They treat football like their personal fiefdom’

The Football Supporters’ Association has slammed plans to reform the structure of English Football, saying the proposals have been “stitched up behind our backs by billionaire club owners” who treat football as their “personal fiefdom”.

English Football League (EFL) chairman Rick Parry along with Liverpool and Manchester United are leading the proposals that would see the Premier League cut from 20 teams to 18.

The EFL would also be given a £250 million ($326m) bailout to cover the losses suffered as a result of the coronavirus pandemic, while The Football Association would receive a one-off £100m ($130m) payment to help deal with the Covid-19 crisis.

However, in exchange, the Premier League’s nine longest-serving teams would be granted special status and the division’s ‘big six’ – Liverpool, United, Arsenal, Chelsea, Manchester City and Tottenham – would be given the collective power to make major changes.

Critics of the proposals see this

Read More

Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency

NEW YORK & MIAMI–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth hormone deficiency (GHD), met its primary endpoint of improved treatment burden compared to GENOTROPIN® (somatropin) for injection administered once-daily.

Top-line results from the study demonstrated that treatment with somatrogon once-weekly improved the mean overall Life Interference total score after 12 weeks of treatment (8.63) compared to treatment with somatropin administered once-daily (24.13). The point estimate of the treatment difference was -15.49 (-19.71, -11.27 (95% CI); p<0.0001) in favor of somatrogon at the nominal 0.05 level. In addition, key secondary endpoints showed an overall benefit in treatment experience with the somatrogon once-weekly dosing regimen compared to the somatropin once-daily dosing regimen.

“We’re encouraged by findings to date that

Read More